Clinical Trial

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial will evaluate the safety of chemoimmunotherapy with Naxitamab and COG-type induction chemotherapy in newly-diagnosed patients with high-risk neuroblastoma. We aim to recruit 10 patients over the next 2 years.
Trial Details
NCT Number NCT07537400
Lead Sponsor Shaare Zedek Medical Center
Collaborators: Y-mAbs Therapeutics
Conditions High-Risk Neuroblastoma
Enrollment 10 participants
Start Date 2026-05
Primary Completion 2028-06 (estimated)
Study Completion 2032-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-17